Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
 shares announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Nov. 29, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in New York on behalf of certain purchasers of shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) over alleged Securities Laws Violations by Alexion Pharmaceuticals, Inc.
Investors who purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) have certain options and for certain investors there are short and strict deadlines running. Deadline: January 17, 2017. NASDAQ: ALXN investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants issued materially false and misleading statements to investors and/or failed to disclose that Alexion Pharmaceuticals, Inc employed improper sales practices with respect to Soliris, that consequently, Alexion’s revenues from Soliris sales were unlikely to be sustainable, and that as a result, Alexion’s public statements were materially false and misleading at all relevant times.
On November 9, 2016, Alexion Pharmaceuticals, Inc announced that the Audit and Finance Committee of the Board of Directors is conducting an investigation into allegations that recently have been made by a former employee with respect to the Company’s sales practices of Soliris. Alexion Pharmaceuticals, Inc said that the Audit and Finance Committee is investigating whether Company personnel have engaged in sales practices that were inconsistent with Company policies and procedures and the related disclosure and other considerations raised by such practices and that the Audit and Finance Committee has retained outside counsel to assist it in the investigation.
Those who purchased Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
